Episodic Neuropathic-Like Musculoskeletal Pain Associated with Ritlecitinib Therapy in Alopecia Universalis: A Case Report

    October 2025 in “ Cureus ”
    Sunil Bhardwaj, Sasank Aramandla, Affan Naveed … D Thinh
    Studysummary In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on cureus.com →
    Discuss this study in the Community →

    Research cited in this study 22

    1. Safety of Oral JAK Inhibitors in Treating Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in Pharmacology · 2025
    2. Alopecia Areata: Pathogenesis, Diagnosis, And Therapies MedComm · 2025
    3. Significant Efficacy of Tofacitinib from China in the Treatment of Alopecia Areata: A Case Report Frontiers in Immunology · 2025
    4. Clinical Presentations and Comorbidities of Pediatric Alopecia Areata Pediatric Dermatology · 2025
    5. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    6. Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study Journal of Cutaneous Immunology and Allergy · 2025
    7. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    8. Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial Journal of the American Academy of Dermatology · 2024
    9. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    10. Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in pharmacology · 2024
    11. Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study Acta dermato-venereologica · 2023
    12. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    13. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    14. Lifestyle Factors Involved in the Pathogenesis of Alopecia Areata International journal of molecular sciences · 2022
    15. Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata International Journal of Molecular Sciences · 2021
    16. Immunology of Alopecia Areata Central-European Journal of Immunology/Central European Journal of Immunology · 2020
    17. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    18. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    19. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    20. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    21. Interventions for Alopecia Areata Cochrane library · 2008
    22. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men Journal of The American Academy of Dermatology · 2007